DiaMedica Therapeutics (DMAC) vs Shattuck Labs (STTK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Shattuck Labs (STTK) has outperformed DiaMedica Therapeutics (DMAC) over the past year, gaining 119.7% versus a gain of 8.1%. Over five years, DMAC leads with a +118.8% price change compared with -52.0% for STTK. Shattuck Labs is the larger company by market cap ($454.2 million vs $445.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DMAC | STTK |
|---|---|---|
| Share price | $8.25 | $4.46 |
| Market cap | $445.15M | $454.22M |
| 1-day change | +2.87% | -1.98% |
| YTD return | +3.64% | +22.19% |
| 1-year return | +8.13% | +119.70% |
| 5-year return | +118.83% | -51.99% |
| EPS (TTM) | $-0.75 | $-0.47 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $1.00M |
| Revenue growth (YoY) | — | -82.52% |
| Net income (latest FY) | $-32.77M | $-48.81M |
| Operating margin | — | -5150.80% |
| Net margin | — | -4880.90% |
| 52-week high | $11.00 | $8.33 |
| 52-week low | $5.25 | $1.93 |
| Distance from 52-week high | -25.00% | -46.46% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +96.97% | +245.29% |
| Average volume | 210.46K | 1.20M |
| Shares outstanding | 53.96M | 101.84M |
| Employees | 35 | 40 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- STTK has outperformed DMAC by 111.6 percentage points over the past year.
About DiaMedica Therapeutics
DMAC stock →DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction.
Health Care · Biotechnology: Pharmaceutical Preparations · 35 employees
About Shattuck Labs
STTK stock →Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study.
Health Care · Biotechnology: Pharmaceutical Preparations · 40 employees
DMAC vs STTK FAQ
Which is bigger, DiaMedica Therapeutics or Shattuck Labs?
Shattuck Labs (STTK) is larger, with a market capitalization of $454.22M compared with $445.15M for DiaMedica Therapeutics (DMAC).
Which stock has performed better over the past year, DMAC or STTK?
STTK returned +119.70% over the past 12 months, compared with +8.13% for DMAC (price return, excluding dividends). Past performance does not predict future results.
Are DiaMedica Therapeutics and Shattuck Labs in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.